Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of GX-I7 in HPV-infected Female Volunteers
NCT03144934Phase 1Completed
- Sponsor
- Genexine
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human papillomavirus infection comparing GX-I7 with Placebo (2 arms). Primary endpoint: Safety and Tolerability at 12 weeks. Started Feb 2017; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03144934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144934.